2. Search Result
Search Result
Results for "

Kv 1.5

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10015
    PAP-1
    Maximum Cited Publications
    13 Publications Verification

    5-(4-Phenoxybutoxy)psoralen

    		 Potassium Channel Inflammation/Immunology
    PAP-1 (5-(4-Phenoxybutoxy)psoralen) is a potent, selective, and orally active Kv1.3 blocker (EC50=2 nM). PAP-1 blocks Kv1.3 in a use-dependent manner and acts by preferentially binding to the C-type inactivated state of the channel. PAP-1 exhibits 23-fold selectivity over Kv1.5 (EC50=45 nM), and further displays 33- to 125-fold selectivity over all other Kv1-family channels. PAP-1 does not exhibit cytotoxic or phototoxic effects .
    PAP-1
  • HY-B0189
    Mosapride
    5+ Cited Publications

    TAK-370; AS-4370

    		 5-HT Receptor Cytochrome P450 Potassium Channel Neurological Disease Cancer
    Mosapride is an orally active gastroenterokinetic compound. Mosapride is a 5HT4 agonist. Mosapride is a CYP inducer. Mosapride has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride can be used in the study of gastrointestinal diseases .
    Mosapride
  • HY-14183
    Vernakalant Hydrochloride
    3 Publications Verification

    RSD1235 hydrochloride

    		 Potassium Channel Cardiovascular Disease
    Vernakalant hydrochloride is a mixed voltage- and frequency-dependent Na + and atria-preferred K + channel blocker. IC50 for block by Vernakalant of wild-type and mutant Kv1.5 channels Fractional block is 13.35±0.93 μM, 0.61±0.03 μM, and 1.63±0.09 μM for Kv1.5 channel wt, Kv1.5 channel I508F, Kv1.5 channel T479A, respectively.
    Vernakalant Hydrochloride
  • HY-100712
    DPO-1
    1 Publications Verification

    		 Potassium Channel Calcium Channel NOD-like Receptor (NLR) Interleukin Related Cardiovascular Disease Inflammation/Immunology
    DPO-1 is a potent Kv1.5 and Kv1.3 (EC50 = 3.1 μM) channels inhibitor with potential immunomodulatory and anti-inflammatory effects. DPO-1 reduces Kv1.3 current density, blunts Ca 2+ influx in Ca 2+-depleted Jurkat cells, and inhibits IL-2 secretion in activated Jurkat cells. DPO-1 inhibits Uric acid sodium (HY-B2130A) (MSU)-induced NLRP3 inflammasome activation by blocking Kv1.5-mediated K + efflux. DPO-1 can be used for the study of immunologic disorders and atrial fibrillation .
    DPO-1
  • HY-B0189A
    Mosapride citrate
    5+ Cited Publications

    TAK-370 citrate; AS-4370 citrate

    		 5-HT Receptor Potassium Channel Cytochrome P450 Neurological Disease Cancer
    Mosapride citrate is an orally active gastroenterokinetic compound. Mosapride citrate is a 5HT4 agonist. Mosapride citrate is a CYP inducer. Mosapride citrate has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride citrate can be used in the study of gastrointestinal diseases .
    Mosapride citrate
  • HY-108587
    ICA 110381

    		Potassium Channel Neurological Disease
    ICA 110381 is an orally active Kv7.2/Kv7.3 (KCNQ2/3) potassium channel activator with anticonvulsive properties. ICA 110381 is a KCNQ2/Q3 activator (EC50=0.38 μM) as well as KCNQ1 antagonist (IC50=15 μM) .
    ICA 110381
  • HY-B0189B
    Mosapride citrate dihydrate
    5+ Cited Publications

    TAK-370 citrate dihydrate; AS-4370 citrate dihydrate

    		 5-HT Receptor Potassium Channel Cytochrome P450 Metabolic Disease Cancer
    Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine4 receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC50 values of 15.2 μM . Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo .
    Mosapride citrate dihydrate
  • HY-108574
    CP 339818 hydrochloride

    		Potassium Channel HCN Channel Neurological Disease
    CP 339818 hydrochloride is a non-peptide Kv1.3 channel (IC50 = 200 nM) and Kv1.4 channel blocker. CP 339818 hydrochloride inhibits HCN channel with IC50s of 18.9 μM and 43.4 μM against HCN1 and HCN4 (high Cl -). CP 339818 hydrochloride has significantly weaker blocking effects on Kv1.1, Kv1.2, Kv1.5, Kv1.6, Kv3.1-4, and Kv4.2 channels. CP 339818 hydrochloride selectively blocked Kv1.3, thereby inhibiting the activation process of human T cells. CP 339818 hydrochloride can be used to study the physiological functions of HCN and Kv channels .
    CP 339818 hydrochloride
  • HY-122033
    MK-0448

    		Potassium Channel Cardiovascular Disease
    MK-0448 is a specific Kv1.5 inhibitor used in the research of atrial fibrillation .
    MK-0448
  • HY-118387
    AVE-0118

    		Potassium Channel Cardiovascular Disease
    AVE-0118 is a Kv1.5 potassium channel blocker and antiarrhythmic agent. AVE-0118 blocks neuronal Kv1.5 potassium channels, thereby enhancing the release of norepinephrine. AVE-0118 enhances field stimulation-induced neurogenic contraction, an effect sensitive to α1-adrenergic receptor blockade. AVE-0118 terminates persistent atrial fibrillation in some dogs. AVE-0118 is applicable to research related to atrial fibrillation and persistent atrial fibrillation .
    AVE-0118
  • HY-10015R
    PAP-1 (Standard)

    5-(4-Phenoxybutoxy)psoralen (Standard)

    		 Reference Standards Potassium Channel Inflammation/Immunology
    PAP-1 (Standard) is the analytical standard of PAP-1. This product is intended for research and analytical applications. PAP-1 (5-(4-Phenoxybutoxy)psoralen) is a potent, selective, and orally active Kv1.3 blocker (EC50=2 nM). PAP-1 blocks Kv1.3 in a use-dependent manner and acts by preferentially binding to the C-type inactivated state of the channel. PAP-1 exhibits 23-fold selectivity over Kv1.5 (EC50=45 nM), and further displays 33- to 125-fold selectivity over all other Kv1-family channels. PAP-1 does not exhibit cytotoxic or phototoxic effects .
    PAP-1 (Standard)
  • HY-123793
    MK-1832

    		Potassium Channel P-glycoprotein Cardiovascular Disease
    MK-1832 (Compound 32) is a selective Kv1.5 inhibitor (IC50 = 86 nM). MK-1832 is a P-glycoprotein substrate. MK-1832 can be used in atrial fibrillation research .
    MK-1832
  • HY-B0189AR
    Mosapride citrate (Standard)

    TAK-370 citrate (Standard); AS-4370 citrate (Standard)

    		 5-HT Receptor Potassium Channel Cytochrome P450 Reference Standards Neurological Disease Cancer
    Mosapride (citrate) (Standard) is the analytical standard of Mosapride (citrate). This product is intended for research and analytical applications. Mosapride citrate is an orally active gastroenterokinetic compound. Mosapride citrate is a 5HT4 agonist. Mosapride citrate is a CYP inducer. Mosapride citrate has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride citrate can be used in the study of gastrointestinal diseases .
    Mosapride citrate (Standard)
  • HY-107036
    BMS-394136

    		Potassium Channel Cardiovascular Disease
    BMS-394136 (compound 1) is a potent inhibitor of Kv 1.5, with an IC50 of 0.05 μM. BMS-394136 is a selective IKur inhibitor. BMS-394136 dose-dependently prolongs atrial effective refractory period (AERP) and action potential duration (APD) without effecting ventricular effective refractory period (VERP). BMS-394136 can be used for acute atrial ischemia research .
    BMS-394136
  • HY-134953
    Mephetyl tetrazole

    		Potassium Channel Cancer
    Mephetyl tetrazole is a potassium channel Kv1.5 blocker, with an IC50 of 330 nM. Mephetyl tetrazole can be used for the research of cancer .
    Mephetyl tetrazole
  • HY-129699
    RH01617

    		Potassium Channel MMP Cardiovascular Disease
    RH01617 is a Kv1.5. potassium channel and MMP-13 inhibitor. RH01617 can be used for research of atrial fibrillation .
    RH01617
  • HY-144802
    DDO-02001

    		Potassium Channel Cardiovascular Disease
    DDO-02001 is a moderately potent Kv1.5 potassium channel inhibitor with an IC50 value of 17.7 μM. DDO-02001 can be used for researching anti-arrhythmia .
    DDO-02001
  • HY-126936
    MSD-D

    		Potassium Channel Cardiovascular Disease
    MSD-D is a potent and frequency-dependent Kv1.5 channel inhibitor with an IC50 value of 0.5 μM. MSD-D is promising for research of atrial-selective class III antiarrhythmics .
    MSD-D
  • HY-114540
    CP-339818

    		Potassium Channel HCN Channel Neurological Disease
    CP-339818 is a non-peptide Kv1.3 channel (IC50 = 200 nM) and Kv1.4 channel blocker. CP 339818 inhibits HCN channel with IC50s of 18.9 μM and 43.4 μM against HCN1 and HCN4 (high Cl -). CP-339818 has significantly weaker blocking effects on Kv1.1, Kv1.2, Kv1.5, Kv1.6, Kv3.1-4, and Kv4.2 channels. CP-339818 selectively blocked Kv1.3, thereby inhibiting the activation process of human T cells. CP-339818 can be used to study the physiological functions of HCN and Kv channels .
    CP-339818
  • HY-136805
    Kv1.5-IN-1

    		Potassium Channel Neurological Disease
    Kv1.5-IN-1 is a Kv1.5 channel inhibitor. Its target selectivity and pharmacodynamic effects were evaluated in an in vitro rat model. After the introduction of a methoxy group at the R5 position, Kv1.5-IN-1 showed inhibitory potency similar to that of the unsubstituted compound. Its IC50 value for hKv1.5 channels was 0.51 μM. Kv1.5-IN-1 exhibited a high degree of selectivity, nearly 2,600 times higher than compound Ik and 300 times higher than compound IId, indicating that it may be a safe inhibitor. Due to its good pharmacological behavior, Kv1.5-IN-1 deserves further pharmacodynamic and pharmacokinetic evaluation. These properties make Kv1.5-IN-1 a potential Kv1.5 channel inhibitor that may have application prospects in the treatment of related diseases.
    Kv1.5-IN-1
  • HY-14186
    KVI-020

    WYE-160020

    		 Potassium Channel Cardiovascular Disease
    KVI-020 is an orally active, potent and selective blocker of the atrial potassium channel Kv1.5, with an IC50 of 480 nM. KVI-020 can inhibits hERG, with an IC50 of 15100 nM. KVI-020 is a potent antiarrhythmic agent, and can be used for atrial fibrillation (AF) research .
    KVI-020
  • HY-144801A
    DDO-02005

    		Potassium Channel Cardiovascular Disease
    DDO-02005 is a potent Kv1.5 potassium channel inhibitor with an IC50 value of 0.72 μM. DDO-02005 has good anti-atrial fibrillation (AF) effect in CaCl2-ACh AF rats model and effective anti-arrhythmic activity caused by aconitine .
    DDO-02005
  • HY-144801
    DDO-02005 free base

    		Potassium Channel Cardiovascular Disease
    DDO-02005 (free base) is a potent Kv1.5 potassium channel inhibitor with an IC50 value of 0.72 μM. DDO-02005 (free base) has good anti-atrial fibrillation (AF) effect in CaCl2-ACh AF rats model and effective anti-arrhythmic activity caused by aconitine .
    DDO-02005 free base
  • HY-172521
    (S)-(+)-Docosahexaenyl-2'-hydroxy-1'-propylamide

    		Potassium Channel Others
    (S)-(+)-Docosahexaenyl-2'-hydroxy-1'-propylamide (N-Docosahexacnoylethanolamide(22:6)) is a DHEA homolog. (S)-(+)-Docosahexaenyl-2'-hydroxy-1'-propylamide blocks the Shaker-related voltage-gated potassium channels. (S)-(+)-Docosahexaenyl-2'-hydroxy-1'-propylamide can inhibit the Kv1.2 K+ currents with an IC50 of 1.5 μM .
    (S)-(+)-Docosahexaenyl-2'-hydroxy-1'-propylamide
  • HY-RS07101
    KCNA5 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KCNA5 Human Pre-designed siRNA Set A contains three designed siRNAs for KCNA5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KCNA5 Human Pre-designed siRNA Set A
    KCNA5 Human Pre-designed siRNA Set A
  • HY-100712R
    DPO-1 (Standard)

    		Potassium Channel Reference Standards Calcium Channel NOD-like Receptor (NLR) Interleukin Related Cardiovascular Disease Inflammation/Immunology
    DPO-1 (Standard) is the analytical standard of DPO-1 (HY-100712). This product is intended for research and analytical applications. DPO-1 is a potent Kv1.5 and Kv1.3 (EC50 = 3.1 μM) channels inhibitor with potential immunomodulatory and anti-inflammatory effects. DPO-1 reduces Kv1.3 current density, blunts Ca2+ influx in Ca2+-depleted Jurkat cells, and inhibits IL-2 secretion in activated Jurkat cells. DPO-1 inhibits Uric acid sodium (HY-B2130A) (MSU)-induced NLRP3 inflammasome activation by blocking Kv1.5-mediated K+ efflux. DPO-1 can be used for the study of immunologic disorders and atrial fibrillation .
    DPO-1 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: